<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00090103</url>
  </required_header>
  <id_info>
    <org_study_id>ARI40005</org_study_id>
    <nct_id>NCT00090103</nct_id>
  </id_info>
  <brief_title>Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment</brief_title>
  <official_title>A Randomized, Double-blind, Parallel Group Study to Investigate the Efficacy and Safety of Treatment With Dutasteride (0.5mg) and Tamsulosin (0.4mg), Administered Once Daily for 4 Years, Alone and Combination, on the Improvement of Symptoms and Clinical Outcome in Men With Moderate to Severe Symptomatic Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy and safety of treatment with dutasteride and
      tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement
      of symptoms and clinical outcome in men with moderate to severe symptomatic Benign Prostatic
      Hyperplasia (BPH). Study visits are every 3 months for up to 4 years (18 clinic visits).
      Transrectal ultrasound (TRUS) is done annually.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomised, double-blind, parallel group study to investigate the efficacy and safety of
      treatment with Dutasteride (0.5 mg) and Tamsulosin (0.4 mg), administered once daily for 4
      years, alone and in combination, on the improvement of symptoms and clinical outcome in men
      with moderate to severe symptomatic benign prostatic hyperplasia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.</measure>
    <time_frame>Years 1, 2, 3, and 4</time_frame>
    <description>A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant-reported or identified, they were recorded in the participants' clinic record.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With AUR or BPH-related Surgery</measure>
    <time_frame>Baseline (Day 1) through Year 4</time_frame>
    <description>A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant reported or identified, they were recorded in the participants' clinic record.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4</measure>
    <time_frame>Years 1, 2, 3, and 4</time_frame>
    <description>The time when the first symptom/event of BPH clinical progression has occurred (i.e. AUR, incontinence) was measured. Summaries are based on the first occuring event after treatment start. The time period is from treatment start to each participant's last treatment visit. The Year 4 events include all those that occur during the fourth year and beyond.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Each of the Five Components of BPH Clinical Progression</measure>
    <time_frame>Baseline (Day 1) to Year 4</time_frame>
    <description>The five components measured were symptom deterioration, BPH-related AUR, BPH-related incontinence, recurrent BPH-related Urinary Tract Infection (UTI), and BPH-related renal insufficiency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Events of Symptom Deterioration at the Indicated Time Periods</measure>
    <time_frame>Years 1, 2, 3, and 4 (from treatment start until each participant's last treatment-phase visit)</time_frame>
    <description>The number of participants (par.) with symptom deterioration of International Prostate Symptom Score (IPSS) ≥4 points on two consecutive visits post-baseline are presented. Data are based on the first occurrence of an event after treatment start. The year-4 events include all that occured during the 4th year and beyond. The IPSS is a 7-item questionnaire measuring the level of urinary symptoms reported as the total score. Each question has a 6-point response scale (0=none/not at all to 5=almost always), with a total score ranging from 0-35: mild (0-7), moderate (8-19), or severe (20-35).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria</measure>
    <time_frame>Baseline (Day 1) through Year 4</time_frame>
    <description>A participant was considered to have macroscopic hematuria when there was presence of blood in the urine. The event of macroscopic hematuria was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related macroscopic hematuria. Participants may appear in both categories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Event of Post-baseline BPH-related Hematospermia</measure>
    <time_frame>Baseline (Day 1) through Year 4</time_frame>
    <description>A participant was considered to have hematospermia when there was presence of blood in the semen. Hematospermia can occur from prostatitis (prostate infection), from cancer, or after a prostate biopsy. The event of hematospermia was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related hematospermia. Participants may appear in both categories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12, 24, 36, and 48</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>The IPSS is a 7-item questionnaire that measures urinary symptoms. It measures the level of urinary symptoms (including incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia) reported as the total IPSS score. Each of the 7 questions has a 6-point response scale (0=none/not at all to 5=almost always) with a total score that can range from 0-35: mild (0-7), moderate (8-19), or severe (20-35). Estimates are based on adjusted (least squares) means from the general linear model: change from baseline IPSS = Treatment + Cluster + Baseline IPSS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12, 24, 36, and 48</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>Peak maximum urinary flow (Qmax) of urinary flow using a Medtronic (formerly Dantec) Uroflow Meter (Urodyn 1000 or Duet models) with a Thompson filter was measured. Estimates are based on adjusted (least squares) means from the general linear model: Change from baseline Qmax = treatment + cluster + baseline Qmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Percent Change From Baseline in Prostate Volume at Months 12, 24, 36, and 48</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>Prostate volume measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total prostate volume centimeters (cc). Percent change from baseline = [(post-baseline - baseline)/baseline value] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: log(post-baseline/baseline value) + treatment + cluster + log(baseline value) and are reported as percent change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12, 24, 36, and 48</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>Prostate volume (PV) measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total PV in centimeters (cc). Results are for the transition zone measurements of the prostate in a small subset of participants. Percent change from baseline (BL) = [(post-BL - BL)/BL value] x 100. Estimates are based on the adjusted (least squares) means for the general linear model: log(post-BL/BL value) = treatment + cluster + log(BL value) and are reported as percent change from BL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit</measure>
    <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
    <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: &quot;Has the participant needed to make any unscheduled visits to his general practitioner (GP)/Urologist regarding AUR symptoms since the last study visit?&quot; If the answer to the question was &quot;yes,&quot; the number of visits was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of &quot;Yes&quot; Responses to the Question: &quot;Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned&quot;?.</measure>
    <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
    <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: &quot;Would the participant have paid a visit to his GP/Urologist regarding AUR symptoms if this study visit had not been planned?&quot;. If the answer to the question was &quot;yes,&quot; the number of Yes responses was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit</measure>
    <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
    <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: &quot;Has the participant needed to visit his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?&quot;. If the answer to the question was &quot;yes,&quot; the number of visits was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of &quot;Yes&quot; Responses to the Question: &quot;Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?&quot;</measure>
    <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
    <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: &quot;Would the participant have paid a visit to his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?&quot;. If the answer to the question was &quot;yes,&quot; the number of Yes responses was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)</measure>
    <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
    <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: &quot;Has the participant had any unplanned GP/Urologist (outpatient) visits that would have taken place if a scheduled study visit had not been planned (this can include visits resulting from UTI, UI macroscopic haematuria, etc?&quot;. If the answer to the question was &quot;yes,&quot; the number of visits was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Unscheduled Visits to GP/Urologist (Outpatient) Planned, Not Relating to the Study (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)</measure>
    <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
    <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: &quot;Does the participant have any unscheduled GP/Urologist (outpatients) visits planned, not relating to the study (this can include visits resulting from UTI, UI, macroscopic haematuria, etc.?&quot;. If the answer to the question was &quot;yes,&quot; the number of visits was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in BPH Impact Index (BII) at Months 12, 24, 36, and 48</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>The BII is a 4-item questionnaire, score range of 0 (best) to 12 (worst) for questions 1-3, and 0 (best) to 13 (worst) for question 4, that assesses the overall impact of BPH on a participant's general sense of well being and measures aspects of physical discomfort, worry, and bother, all of which can be affected by BPH and its symptoms. BII score = sum of questions 1-4. Change from baseline = Post-Baseline Value. Estimates are based on the adjusted (least squares) means from the general linear model: change from baseline BII = treatment + cluster + baseline BII.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change From Baseline in BPH-Related Health Status (BHS) at Months 12, 24, 36, and 48</measure>
    <time_frame>Baseline and Months 12, 24, 36, 48</time_frame>
    <description>The effect of study treatment on BHS was assessed by using three self-administered questionnaires: the International Prostate Symptom Score (IPSS), the BPH Impact Index (BII), and Patient Perception of Study Medication (PPSM). The BHS score was collected on the IPPS questionnaire and ranged from 0 (best) to 6 (worst). Percent change from baseline = [(post-baseline - baseline)/baseline value] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: change from baseline BPH-related health status = treatment + cluster + baseline BPH-Related health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 1 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has control of your urinary problems changed?&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 2 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect of the study medication on control of your urinary problems?&quot; Satisfact., satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 3 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has the strength of your urinary stream changed?&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 4 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect of the study medication on the strength of your urinary stream?&quot;. Satisfact., satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 5 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has your pain prior to urinating changed?&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 6 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect the study medication has on your pain prior to urinating?&quot;. Satisfact., satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 7 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has your pain during urination changed?&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 8 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect the study medication has on your pain during urination?&quot;. Satisfact., satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 9 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has the way your urinary problems interfere with your ability to go about your usual activities changed?&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 10 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect the study medication has on your ability to go about your usual activities without interference from your urinary problems?&quot;. Satisfact., satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 11 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Overall, how satisfied are you with the study medication and it's effect on your urinary problems?&quot;. Satisfact., satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 12 (LOCF)</measure>
    <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
    <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Would you ask your doctor for the medication you received in this study?&quot;.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4844</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>dutasteride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dutasteride 0.5mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of dutasteride (0.5mg) and tamsulosin (0.4mg), once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tamsulosin 0.4mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dutasteride 0.5mg once daily for 4 years</intervention_name>
    <description>combination or single agent</description>
    <arm_group_label>Combo</arm_group_label>
    <arm_group_label>dutasteride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamsulosin 0.4mg once daily for 4 years</intervention_name>
    <description>combination agent or single agent</description>
    <arm_group_label>Combo</arm_group_label>
    <arm_group_label>tamsulosin</arm_group_label>
    <other_name>dutasteride</other_name>
    <other_name>tamsulosin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  A subject will be considered eligible for inclusion in this study only if all of the
             following criteria apply:

          -  males, aged ≥50 years

          -  clinical diagnosis of BPH by medical history and physical examination, including a
             digital rectal examination (DRE)

          -  International Prostate Symptom Score (IPSS) ≥12 points at Screening

          -  prostate volume ≥30 cc by transrectal ultrasonography; (TRUS)

          -  total serum Prostate Specific Antigen (PSA) ≥1.5ng/mL at Screening

          -  maximum flow rate (Qmax) &gt;5 mL/sec and ≤15 mL/sec and minimum voided volume of ≥125 mL
             at Screening (based on two voids)

          -  willing and able to give written informed consent and comply with study procedures

          -  fluent and literate in local language with the ability to read, comprehend and record
             information on the IPSS, BII and Patient Perception of Study Medication

          -  able to swallow and retain oral medication

          -  willing and able to participate in the study for the full 4 years.

        Exclusion Criteria:

        A subject will not be eligible for inclusion in this study if any of the following criteria
        apply:

          -  total serum PSA &gt;10.0ng/mL at Screening

          -  history or evidence of prostate cancer (e.g. positive biopsy or ultrasound, suspicious
             DRE). Patients with suspicious ultrasound or DRE who have had a negative biopsy within
             the preceding 6 months and stable PSA are eligible for the study.

        Note: If total serum PSA is &gt;4ng/mL and unless PSA value has been stable for at least the
        past 2 years, the investigator should make every appropriate effort to exclude the
        possibility of prostate cancer, e.g. further DRE, review TRUS taken within previous month,
        consider 8-12 core prostate biopsy in accordance with routine clinical practice.

          -  previous prostatic surgery (including TURP, balloon dilatation, thermotherapy and
             stent replacement) or other invasive procedures to treat BPH.

          -  history of flexible/rigid cystoscopy or other instrumentation of the urethra within 7
             days prior to the Screening Visit. Routine catheterisation is acceptable with no time
             restriction.

          -  history of AUR within 3 months prior to Screening Visit.

          -  post-void residual volume &gt;250mL (suprapubic ultrasound) at Screening.

          -  any causes other than BPH, which may in the judgement of the investigator, result in
             urinary symptoms or changes in flow rate (e.g. neurogenic bladder, bladder neck
             contracture, urethral stricture, bladder malignancy, acute or chronic prostatitis, or
             acute or chronic urinary tract infections).

          -  history of breast cancer or clinical breast examination finding of unclear origin or
             suggestive of malignancy.

          -  use of any 5-alpha-reductase inhibitor (e.g. Proscar®, Propecia®, Avodart®), any drugs
             with antiandrogenic properties (e.g. spironolactone, flutamide, bicalutamide,
             cimetidine, ketoconazole, metronidazole, progestational agents), or other drugs which
             affect prostate volume, within past 6 months of the Screening Visit and throughout the
             study (other than as study medication).

          -  concurrent use of anabolic steroids

          -  use of phytotherapy for BPH within 2 weeks of Screening Visit and/or predicted to need
             phytotherapy during the study.

          -  use of any alpha-adrenoreceptor blockers (i.e. indoramin, prazosin, terazosin,
             tamsulosin, alfuzosin and doxazosin) within 2 weeks of Screening Visit and/or
             predicted to need any alpha blockers other than tamsulosin during the study.

        Note: the purpose of this criteria is to be able to standardise baseline symptom severity
        for all enrolled patients prior to randomisation and not to specifically exclude current
        alpha-adrenoreceptor blocker users from participation in the study.

          -  use of any alpha-adrenoreceptor agonists (e.g. pseudoephedrine, phenylephrine,
             ephedrine) or anticholinergics (e.g. oxybutynin, propantheline) or cholinergics (e.g.
             bethanecol chloride) within 48 hours prior to all uroflowmetry assessments.

          -  hypersensitivity to any alpha-/beta- adrenoreceptor blocker or 5-alpha-reductase
             inhibitor, or other chemically-related drugs.

          -  concurrent use of drugs known or thought to have an interaction with tamsulosin, e.g.
             cimetidine and warfarin.

          -  history of hepatic impairment or abnormal liver function tests at Screening defined as
             alanine aminotransferase (ALT), aspartate aminotranferase (AST), and/or alkaline
             phosphatase &gt;2 times the upper limit of normal, or total bilirubin &gt;1.5 times the
             upper limit of normal (unless associated with predominantly indirect bilirubin
             elevation or Gilbert's syndrome).

          -  history of renal insufficiency, or serum creatinine &gt;1.5 times the upper limit of
             normal or serum creatinine ≥1.5 mg/dL at Screening.

          -  prior history of malignancies other than basal cell carcinoma or squamous cell
             carcinoma of the skin within the past 5 years. Subjects with a prior malignancy who
             have had no evidence of disease for at least the past 5 years are eligible.

          -  history of any illness that in the opinion of the investigator might confound the
             results of the study or poses additional risk to the patient.

          -  any unstable, serious co-existing medical condition(s) including, but not limited to,
             myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias,
             clinically evident congestive heart failure, or cerebrovascular accident within 6
             months prior to Screening visit; uncontrolled diabetes or peptic ulcer disease which
             is uncontrolled by medical management.

          -  history of postural hypotension, dizziness, vertigo or any other signs and symptoms of
             orthostasis, which in the opinion of the investigator could be exacerbated by
             tamsulosin and result in putting the subject at risk of injury.

          -  history of unsuccessful treatment with tamsulosin or 'first dose' hypotensive episode
             on initiation of alpha-1-adrenoreceptor antagonist therapy.

          -  history of unsuccessful treatment with finasteride or dutasteride

          -  history or current evidence of drug or alcohol abuse within the previous 12 months.

          -  participation in any investigational or marketed drug trial within 30 days (or 5
             half-lives whichever is the longer) preceding the Screening Visit and/or during the
             course of this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbiana</city>
        <state>Alabama</state>
        <zip>35051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix, Arizona</city>
        <state>Arizona</state>
        <zip>86106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glendora</city>
        <state>California</state>
        <zip>91741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laguna Woods</city>
        <state>California</state>
        <zip>92637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angelas</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95821</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>91405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <zip>32168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pinecrest</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spring Hill</city>
        <state>Florida</state>
        <zip>34609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34996</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calhoun</city>
        <state>Georgia</state>
        <zip>30701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belleville</city>
        <state>Illinois</state>
        <zip>62220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wheaton</city>
        <state>Illinois</state>
        <zip>60187</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winfield</city>
        <state>Illinois</state>
        <zip>60190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Kentucky</state>
        <zip>42071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laurel</city>
        <state>Maryland</state>
        <zip>20724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <zip>39466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perth Amboy</city>
        <state>New Jersey</state>
        <zip>08861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somerville</city>
        <state>New Jersey</state>
        <zip>08876</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bayshore</city>
        <state>New York</state>
        <zip>11706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lewiston</city>
        <state>New York</state>
        <zip>14092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <zip>27203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bismarck</city>
        <state>North Dakota</state>
        <zip>58501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bellbrook</city>
        <state>Ohio</state>
        <zip>45305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <zip>19522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athes</city>
        <state>Texas</state>
        <zip>75751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Brunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Texarkana</city>
        <state>Texas</state>
        <zip>75503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mountlake Terrace</city>
        <state>Washington</state>
        <zip>98043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1111</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1120</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1416</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1181ACI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <zip>1405</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <zip>1118</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-008</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90470-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20 551-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04262-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431/1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Varna</city>
        <zip>9002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 4S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kentville</city>
        <state>Nova Scotia</state>
        <zip>B4N 4K9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brantford</city>
        <state>Ontario</state>
        <zip>N3R 4N3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Courtice</city>
        <state>Ontario</state>
        <zip>L1E 3C3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>M6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 7K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1P 2T7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1S 4V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 4T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M2K 2W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 5T2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 3B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6S 4W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3S 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Charles-Borromee</city>
        <state>Quebec</state>
        <zip>J6E 6J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Jerome</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trois Rivieres</city>
        <state>Quebec</state>
        <zip>G9A 3V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>536 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostrava - Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 18</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 8</city>
        <zip>180 71</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roudnice nad Labem</city>
        <zip>413 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fredericia</city>
        <zip>7000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randers</city>
        <zip>8900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>1162</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00150</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kouvola</city>
        <zip>45200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pietarsaari</city>
        <zip>68600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bully Les Mines</city>
        <state>Nord-Pas-de-Calais</state>
        <zip>62160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Agny</city>
        <zip>62217</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athis Mons Cedex</city>
        <zip>91200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bouchemaine</city>
        <zip>49080</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Broglie</city>
        <zip>27270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Castelneau Le Nez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chambery</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chilly Mazarin</city>
        <zip>91380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cournonterral</city>
        <zip>34460</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Créteil cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Domarin</city>
        <zip>38300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Epinay sur Orge</city>
        <zip>91360</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evreux Cedex</city>
        <zip>27025</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Evreux</city>
        <zip>27000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gif-sur-Yvette</city>
        <zip>91190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grenoble</city>
        <zip>38100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Seyne sur Mer</city>
        <zip>83500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lamarque</city>
        <zip>33460</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laval</city>
        <zip>53000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Brusc</city>
        <zip>83140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Les Mureaux</city>
        <zip>78130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lesparre Médoc</city>
        <zip>33340</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linas</city>
        <zip>91310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Longpont sur Orge</city>
        <zip>91310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melun</city>
        <zip>77007</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Meudon</city>
        <zip>92190</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Meylan</city>
        <zip>38240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montauban</city>
        <zip>82017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpelier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orléans Cedex 2</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pontonx Sur Adour</city>
        <zip>40465</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roanne</city>
        <zip>42300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Chamond</city>
        <zip>42400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Denis</city>
        <zip>93200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Galmier</city>
        <zip>42330</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Germain Lespinasse</city>
        <zip>42640</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Sebastien de Morsent</city>
        <zip>27180</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Egrève</city>
        <zip>38120</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Georges d'Orques</city>
        <zip>34680</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sainte Suzanne</city>
        <zip>53270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sanary</city>
        <zip>83110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sarlat la Canéda</city>
        <zip>24200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seysses</city>
        <zip>31600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Six-Fours les Plages</city>
        <zip>83140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suresnes Cedex</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulon</city>
        <zip>83200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vaucresson</city>
        <zip>92420</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Verneuil-sur-Seine</city>
        <zip>78480</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villeneuve-Les-Maguelone</city>
        <zip>34750</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vourey</city>
        <zip>38210</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73430</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Konstanz</city>
        <state>Baden-Wuerttemberg</state>
        <zip>78464</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mosbach</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74821</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rottweil</city>
        <state>Baden-Wuerttemberg</state>
        <zip>78628</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockach</city>
        <state>Baden-Wuerttemberg</state>
        <zip>78333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aichach</city>
        <state>Bayern</state>
        <zip>86551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amberg</city>
        <state>Bayern</state>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Graefeling</city>
        <state>Bayern</state>
        <zip>82166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Neu-Ulm</city>
        <state>Bayern</state>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schongau</city>
        <state>Bayern</state>
        <zip>86956</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wertingen</city>
        <state>Bayern</state>
        <zip>86637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hagenow</city>
        <state>Brandenburg</state>
        <zip>19230</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lauchhammer</city>
        <state>Brandenburg</state>
        <zip>01979</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oranienburg</city>
        <state>Brandenburg</state>
        <zip>16515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Senftenberg</city>
        <state>Brandenburg</state>
        <zip>01968</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alzenau</city>
        <state>Hessen</state>
        <zip>63755</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fulda</city>
        <state>Hessen</state>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Giessen</city>
        <state>Hessen</state>
        <zip>35390</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34123</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koenigstein</city>
        <state>Hessen</state>
        <zip>61462</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35039</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schwalbach</city>
        <state>Hessen</state>
        <zip>65824</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grimmen</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>18507</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parchim</city>
        <state>Mecklenburg-Vorpommern</state>
        <zip>19370</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Delmenhorst</city>
        <state>Niedersachsen</state>
        <zip>27753</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Holzminden</city>
        <state>Niedersachsen</state>
        <zip>37603</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oldenburg</city>
        <state>Niedersachsen</state>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Osnabrueck</city>
        <state>Niedersachsen</state>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duelmen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stadtlohn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48703</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koblenz</city>
        <state>Rheinland-Pfalz</state>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>06114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hettstedt</city>
        <state>Sachsen-Anhalt</state>
        <zip>06333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Merseburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>06217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hohenstein-Ernsttal</city>
        <state>Sachsen</state>
        <zip>09337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Husum</city>
        <state>Schleswig-Holstein</state>
        <zip>25813</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Apolda</city>
        <state>Thueringen</state>
        <zip>99510</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10719</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12681</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>115 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>115 22</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>15126</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>154 52</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Patra</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Polygyros</city>
        <zip>63 100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thassaloniki</city>
        <zip>564 34</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1036.</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sopron</city>
        <zip>9400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Székesfehérvár</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reykjavik</city>
        <zip>101</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Avellino</city>
        <state>Campania</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Castellamare di Stabia (NA)</city>
        <state>Campania</state>
        <zip>80053</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Felice a Cancello Caserta</city>
        <state>Campania</state>
        <zip>81027</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torre del Greco (NA)</city>
        <state>Campania</state>
        <zip>80059</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Modena</city>
        <state>Emilia-Romagna</state>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia-Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lecco</city>
        <state>Lombardia</state>
        <zip>23100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ivrea (TO)</city>
        <state>Piemonte</state>
        <zip>10015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Acireale (CT)</city>
        <state>Sicilia</state>
        <zip>95124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bagno a Ripoli (FI)</city>
        <state>Toscana</state>
        <zip>50126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siena</city>
        <state>Toscana</state>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portogruaro (VE)</city>
        <state>Veneto</state>
        <zip>30026</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-47144</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-49287</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-10207</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zapopan, Jalisco</city>
        <state>Jalisco</state>
        <zip>45100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45170</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico DF</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico, D.F.</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mexico</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amstelveen</city>
        <zip>1186 AM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1034 CS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arnhem</city>
        <zip>6842 CV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Den Haag</city>
        <zip>2566 MJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Doetinchem</city>
        <zip>7009 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Enschede</city>
        <zip>7511JX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Etten-leur</city>
        <zip>4872 LA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9721 SW</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hilversum</city>
        <zip>1213 XZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoofddorp</city>
        <zip>2134 TM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Veldhoven</city>
        <zip>5504 DB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winterswijk</city>
        <zip>7101 BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalesund</city>
        <zip>N-6026</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5094</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bodø</city>
        <zip>N-8009</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haugesund</city>
        <zip>5507</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moelv</city>
        <zip>N-2390</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nøtterøy</city>
        <zip>3128</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0257 OSLO</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0514</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porsgrunn</city>
        <zip>N-3922</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tønsberg</city>
        <zip>3116</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manila</city>
        <zip>1003</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1101</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-221</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-826</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-950</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-043</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Abrantes</city>
        <zip>2200 Abrantes</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1069-166</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1269-098 Lisboa</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-004</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto</city>
        <zip>4150-113 PORTO</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>S. Martinho do Bispo</city>
        <zip>3040-316 Coimbra</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santurce</city>
        <zip>00907</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arad</city>
        <zip>310175</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>105229</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>109472</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117 837</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>125206</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rostov-na-Donu</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>041 66</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skalica</city>
        <zip>909 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zilina</city>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <zip>8001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Claremont</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sunninghill</city>
        <zip>2157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alava</city>
        <zip>01004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alcázar de San Juan (Ciudad Real)</city>
        <zip>13600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badajoz</city>
        <zip>6080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burgos</city>
        <zip>09005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elche (Alicante)</city>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gijon</city>
        <zip>33394</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jerez de la Frontera</city>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Langreo (Oviedo)</city>
        <zip>33920</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <zip>35016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Palmas</city>
        <zip>35020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manacor (Palma de Mallorca)</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marbella</city>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mendaro, Guipuzcoa</city>
        <zip>20850</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Merida</city>
        <zip>6800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sabadell (Barcelona)</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Sebastian</city>
        <zip>20012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Sebastián</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santander</city>
        <zip>38008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tortosa</city>
        <zip>43500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vigo (Pontevedra)</city>
        <zip>30211</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vigo/Pontevedra</city>
        <zip>36200</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vitoria</city>
        <zip>01009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vizcaya</city>
        <zip>48902</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiangmai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sousse</city>
        <zip>4054</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tunis</city>
        <zip>1007</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tunis</city>
        <zip>1008</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sıhhiye/Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Swansea</city>
        <state>Glamorgan</state>
        <zip>SA4 4NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buckshaw Village, Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <state>Midlothian</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX2 6PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chichester</city>
        <state>Sussex West</state>
        <zip>PO19 4SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clydebank, Glasgow</city>
        <zip>G81 2DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edgbaston, Birmingham</city>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo, Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Iceland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Tunisia</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Antoñanzas F, Brenes F, Molero JM, Fernández-Pro A, Huerta A, Palencia R, Cozar JM. [Cost-effectiveness of the combination therapy of dutasteride and tamsulosin in the treatment of benign prostatic hyperlasia in Spain]. Actas Urol Esp. 2011 Feb;35(2):65-71. doi: 10.1016/j.acuro.2010.11.008. Epub 2011 Jan 26. Spanish.</citation>
    <PMID>21269736</PMID>
  </reference>
  <reference>
    <citation>Barkin J, Roehrborn CG, Siami P, Haillot O, Morrill B, Black L, Montorsi F; CombAT Study Group. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int. 2009 Apr;103(7):919-26. doi: 10.1111/j.1464-410X.2009.08196.x. Epub 2009 Feb 23.</citation>
    <PMID>19239460</PMID>
  </reference>
  <reference>
    <citation>Bjerklund Johansen TE, Baker TM, Black LK. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the Combination of Avodart and Tamsulosin trial. BJU Int. 2012 Mar;109(5):731-8. doi: 10.1111/j.1464-410X.2011.10511.x. Epub 2011 Sep 20.</citation>
    <PMID>21933326</PMID>
  </reference>
  <reference>
    <citation>Black L, Grove A, Morrill B. The psychometric validation of a US English satisfaction measure for patients with benign prostatic hyperplasia and lower urinary tract symptoms. Health Qual Life Outcomes. 2009 Jun 19;7:55. doi: 10.1186/1477-7525-7-55.</citation>
    <PMID>19545384</PMID>
  </reference>
  <reference>
    <citation>Chung BH, Roehrborn CG, Siami P, Major-Walker K, Morrill BB, Wilson TH, Montorsi F. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis. 2009;12(2):152-9. doi: 10.1038/pcan.2008.49. Epub 2008 Sep 23.</citation>
    <PMID>18813219</PMID>
  </reference>
  <reference>
    <citation>Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19. Erratum in: Eur Urol. 2010 Nov;58(5):801.</citation>
    <PMID>19825505</PMID>
  </reference>
  <reference>
    <citation>Roehrborn CG, Andriole GL, Wilson TH, Castro R, Rittmaster RS. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol. 2011 Feb;59(2):244-9. doi: 10.1016/j.eururo.2010.10.040. Epub 2010 Nov 4.</citation>
    <PMID>21093145</PMID>
  </reference>
  <reference>
    <citation>Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int. 2011 Mar;107(6):946-54. doi: 10.1111/j.1464-410X.2011.10124.x. Epub 2011 Feb 18.</citation>
    <PMID>21332630</PMID>
  </reference>
  <reference>
    <citation>Roehrborn CG, Wilson TH, Black LK. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial. J Urol. 2012 May;187(5):1732-8. doi: 10.1016/j.juro.2011.12.083. Epub 2012 Mar 15.</citation>
    <PMID>22425127</PMID>
  </reference>
  <reference>
    <citation>Becher E, Roehrborn CG, Siami P, Gagnier RP, Wilson TH, Montorsi F. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis. 2009;12(4):369-74. doi: 10.1038/pcan.2009.37. Epub 2009 Sep 1.</citation>
    <PMID>19901936</PMID>
  </reference>
  <reference>
    <citation>Montorsi F, Roehrborn C, Garcia-Penit J, Borre M, Roeleveld TA, Alimi JC, Gagnier P, Wilson TH. The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU Int. 2011 May;107(9):1426-31. doi: 10.1111/j.1464-410X.2011.10129.x. Epub 2011 Feb 23.</citation>
    <PMID>21348912</PMID>
  </reference>
  <reference>
    <citation>Montorsi F, Henkel T, Geboers A, Mirone V, Arrosagaray P, Morrill B, Black L. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract. 2010 Jul;64(8):1042-51. doi: 10.1111/j.1742-1241.2010.02428.x. Epub 2010 May 7.</citation>
    <PMID>20487046</PMID>
  </reference>
  <reference>
    <citation>Haillot O, Fraga A, Maciukiewicz P, Pushkar D, Tammela T, Höfner K, Chantada V, Gagnier P, Morrill B. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. Prostate Cancer Prostatic Dis. 2011 Dec;14(4):302-6. doi: 10.1038/pcan.2011.13. Epub 2011 Apr 19.</citation>
    <PMID>21502969</PMID>
  </reference>
  <reference>
    <citation>Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F; CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008 Feb;179(2):616-21; discussion 621. Epub 2007 Dec 21. Erratum in: J Urol. 2008 Sep;180(3):1191.</citation>
    <PMID>18082216</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2004</study_first_submitted>
  <study_first_submitted_qc>August 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2004</study_first_posted>
  <results_first_submitted>February 26, 2010</results_first_submitted>
  <results_first_submitted_qc>February 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 16, 2010</results_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combination Therapy</keyword>
  <keyword>dutasteride</keyword>
  <keyword>BPH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_id>ARI40005</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARI40005</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARI40005</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARI40005</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARI40005</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARI40005</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>ARI40005</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>In a 4-week, single-blind placebo run-in period, all participants (par.) took two capsules consisting of one dutasteride-matched placebo capsule and one tamsulosin-matched placebo capsule once daily for 4 weeks. A safety follow-up was performed for all participants 16 weeks after the last dose of study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
          <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
        </group>
        <group group_id="P2">
          <title>Dutasteride 0.5 mg</title>
          <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
        </group>
        <group group_id="P3">
          <title>Tamsulosin 0.4 mg</title>
          <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Four-Year Double-Blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1610"/>
                <participants group_id="P2" count="1623"/>
                <participants group_id="P3" count="1611"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1113"/>
                <participants group_id="P2" count="1093"/>
                <participants group_id="P3" count="989"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="497"/>
                <participants group_id="P2" count="530"/>
                <participants group_id="P3" count="622"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="185"/>
                <participants group_id="P3" count="210"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="114"/>
                <participants group_id="P2" count="160"/>
                <participants group_id="P3" count="148"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="104"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Relocated</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closed/Sponsor Termination</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant/Medication Interruption</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prostate Surgery/TURP/Alt. Therapy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Decision/Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Acute Urinary Retention (AUR)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prohibited Medication</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Departure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alcohol Dependent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Improvement</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>BPH/BPH symptoms worse/urinary incont.</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Financial Problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Loss of Libido</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Angina Pectoris</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Loss of Contact</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Neoplasm of Bladder/Prostate</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Cardiologist/Neurologist Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Renal Insufficiency</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Back Pain</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Scheduling Issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Any Appreciable Improvement</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrollment Error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Urinary Tract Infection (UTI)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prostate Specific Antigen Rising</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>16-Week Safety Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1598">Some par. didn't enter the Follow-up phase or dropped out before completing the treatment phase.</participants>
                <participants group_id="P2" count="1615">Some par. didn't enter the Follow-up phase or dropped out before completing the treatment phase.</participants>
                <participants group_id="P3" count="1600">Some par. didn't enter the Follow-up phase or dropped out before completing the treatment phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1224"/>
                <participants group_id="P2" count="1205"/>
                <participants group_id="P3" count="1143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="374"/>
                <participants group_id="P2" count="410"/>
                <participants group_id="P3" count="457"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="185"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="229"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="97"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closed/Sponsor Termination</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant/Medication Interruption</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Loss of Contact</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression/Treatment Failure</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant relocated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Decision/Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prohibited Medication</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alcohol Dependent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prostate surgery/TURP/Alt. therapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Loss of Libido</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Enrollment Error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Neoplasm of Bladder/Prostate Cancer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Gyneomastia</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Acute Urinary Retention (AUR)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>BPH/BPH symptoms worse/urinary incont.</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Angina Pectoris</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Back Pain</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Scheduling Issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator/Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Depression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Diabetes Uncontrolled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Jailed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
          <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
        </group>
        <group group_id="B2">
          <title>Dutasteride 0.5 mg</title>
          <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
        </group>
        <group group_id="B3">
          <title>Tamsulosin 0.4 mg</title>
          <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1610"/>
            <count group_id="B2" value="1623"/>
            <count group_id="B3" value="1611"/>
            <count group_id="B4" value="4844"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.0" spread="7.05"/>
                    <measurement group_id="B2" value="66.0" spread="6.99"/>
                    <measurement group_id="B3" value="66.2" spread="7.00"/>
                    <measurement group_id="B4" value="66.1" spread="7.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1610"/>
                    <measurement group_id="B2" value="1623"/>
                    <measurement group_id="B3" value="1611"/>
                    <measurement group_id="B4" value="4844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1421"/>
                    <measurement group_id="B2" value="1433"/>
                    <measurement group_id="B3" value="1405"/>
                    <measurement group_id="B4" value="4259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.</title>
        <description>A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant-reported or identified, they were recorded in the participants' clinic record.</description>
        <time_frame>Years 1, 2, 3, and 4</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants randomized to the double-blind treatment period. As the study progressed, participants dropped out of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.</title>
          <description>A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant-reported or identified, they were recorded in the participants' clinic record.</description>
          <population>Intent-to-Treat (ITT) Population: all participants randomized to the double-blind treatment period. As the study progressed, participants dropped out of the study.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1610"/>
                <count group_id="O2" value="1623"/>
                <count group_id="O3" value="1611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1, n=1610, 1623, 1611</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2, n=1457, 1484, 1464</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3, n=1347, 1365, 1307</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4, n=1274, 1277, 1176</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>Log-rank test with stratification by cluster.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Relative Risk Estimate</param_type>
            <param_value>0.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.58</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Log-rank test with stratification by cluster.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Relative Risk Estimate</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.26</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4</title>
        <description>The time when the first symptom/event of BPH clinical progression has occurred (i.e. AUR, incontinence) was measured. Summaries are based on the first occuring event after treatment start. The time period is from treatment start to each participant's last treatment visit. The Year 4 events include all those that occur during the fourth year and beyond.</description>
        <time_frame>Years 1, 2, 3, and 4</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4</title>
          <description>The time when the first symptom/event of BPH clinical progression has occurred (i.e. AUR, incontinence) was measured. Summaries are based on the first occuring event after treatment start. The time period is from treatment start to each participant's last treatment visit. The Year 4 events include all those that occur during the fourth year and beyond.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1610"/>
                <count group_id="O2" value="1623"/>
                <count group_id="O3" value="1611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1, n=1610, 1623, 1611</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="184"/>
                    <measurement group_id="O3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2, n= 1264, 1240, 1262</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3, n=1135, 1082, 1048</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4, n= 1047, 959, 880</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With AUR or BPH-related Surgery</title>
        <description>A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant reported or identified, they were recorded in the participants' clinic record.</description>
        <time_frame>Baseline (Day 1) through Year 4</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AUR or BPH-related Surgery</title>
          <description>A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant reported or identified, they were recorded in the participants' clinic record.</description>
          <population>ITT Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1610"/>
                <count group_id="O2" value="1623"/>
                <count group_id="O3" value="1611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPH-related surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>Log rank test with stratification by cluster.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Log rank test with stratification by cluster.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Each of the Five Components of BPH Clinical Progression</title>
        <description>The five components measured were symptom deterioration, BPH-related AUR, BPH-related incontinence, recurrent BPH-related Urinary Tract Infection (UTI), and BPH-related renal insufficiency.</description>
        <time_frame>Baseline (Day 1) to Year 4</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Each of the Five Components of BPH Clinical Progression</title>
          <description>The five components measured were symptom deterioration, BPH-related AUR, BPH-related incontinence, recurrent BPH-related Urinary Tract Infection (UTI), and BPH-related renal insufficiency.</description>
          <population>ITT Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1610"/>
                <count group_id="O2" value="1623"/>
                <count group_id="O3" value="1611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Symptom deterioration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="203"/>
                    <measurement group_id="O3" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPH-related AUR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPH-related incontinence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recurrent BPH-related UTI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPH-related renal insufficiency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of Symptom Deterioration at the Indicated Time Periods</title>
        <description>The number of participants (par.) with symptom deterioration of International Prostate Symptom Score (IPSS) ≥4 points on two consecutive visits post-baseline are presented. Data are based on the first occurrence of an event after treatment start. The year-4 events include all that occured during the 4th year and beyond. The IPSS is a 7-item questionnaire measuring the level of urinary symptoms reported as the total score. Each question has a 6-point response scale (0=none/not at all to 5=almost always), with a total score ranging from 0-35: mild (0-7), moderate (8-19), or severe (20-35).</description>
        <time_frame>Years 1, 2, 3, and 4 (from treatment start until each participant's last treatment-phase visit)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all participants randomized to the double-blind treatment period. As the study progressed, participants dropped out of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of Symptom Deterioration at the Indicated Time Periods</title>
          <description>The number of participants (par.) with symptom deterioration of International Prostate Symptom Score (IPSS) ≥4 points on two consecutive visits post-baseline are presented. Data are based on the first occurrence of an event after treatment start. The year-4 events include all that occured during the 4th year and beyond. The IPSS is a 7-item questionnaire measuring the level of urinary symptoms reported as the total score. Each question has a 6-point response scale (0=none/not at all to 5=almost always), with a total score ranging from 0-35: mild (0-7), moderate (8-19), or severe (20-35).</description>
          <population>Intent-to-Treat (ITT) Population: all participants randomized to the double-blind treatment period. As the study progressed, participants dropped out of the study.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1610"/>
                <count group_id="O2" value="1623"/>
                <count group_id="O3" value="1611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1, n=1610, 1623, 1611</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2, n=1286, 1278, 1296</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3, n=1158, 1132, 1088</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4, n=1083, 1001, 926</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <method_desc>Log-rank test with stratification by cluster.</method_desc>
            <param_type>Relative Risk Estimate</param_type>
            <param_value>0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Log Rank</method>
            <param_type>Relative Risk Estimate</param_type>
            <param_value>0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria</title>
        <description>A participant was considered to have macroscopic hematuria when there was presence of blood in the urine. The event of macroscopic hematuria was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related macroscopic hematuria. Participants may appear in both categories.</description>
        <time_frame>Baseline (Day 1) through Year 4</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria</title>
          <description>A participant was considered to have macroscopic hematuria when there was presence of blood in the urine. The event of macroscopic hematuria was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related macroscopic hematuria. Participants may appear in both categories.</description>
          <population>ITT Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1610"/>
                <count group_id="O2" value="1623"/>
                <count group_id="O3" value="1611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall crude rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-BPH-related Crude Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPH-Related Crude Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Log Rank</method>
            <method_desc>Mantel-Haenszel test with stratification by cluster.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Log Rank</method>
            <method_desc>Mantel-Hanenszel test with stratification by cluster.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Event of Post-baseline BPH-related Hematospermia</title>
        <description>A participant was considered to have hematospermia when there was presence of blood in the semen. Hematospermia can occur from prostatitis (prostate infection), from cancer, or after a prostate biopsy. The event of hematospermia was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related hematospermia. Participants may appear in both categories.</description>
        <time_frame>Baseline (Day 1) through Year 4</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event of Post-baseline BPH-related Hematospermia</title>
          <description>A participant was considered to have hematospermia when there was presence of blood in the semen. Hematospermia can occur from prostatitis (prostate infection), from cancer, or after a prostate biopsy. The event of hematospermia was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related hematospermia. Participants may appear in both categories.</description>
          <population>ITT Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1610"/>
                <count group_id="O2" value="1623"/>
                <count group_id="O3" value="1611"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Crude Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-BPH-related Crude Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BPH-related Crude Rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <method>Log Rank</method>
            <method_desc>Mantel-Haenszel test with stratification by cluster.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <method>Log Rank</method>
            <method_desc>Mantel-Haenszel test with stratification by cluster.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12, 24, 36, and 48</title>
        <description>The IPSS is a 7-item questionnaire that measures urinary symptoms. It measures the level of urinary symptoms (including incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia) reported as the total IPSS score. Each of the 7 questions has a 6-point response scale (0=none/not at all to 5=almost always) with a total score that can range from 0-35: mild (0-7), moderate (8-19), or severe (20-35). Estimates are based on adjusted (least squares) means from the general linear model: change from baseline IPSS = Treatment + Cluster + Baseline IPSS.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12, 24, 36, and 48</title>
          <description>The IPSS is a 7-item questionnaire that measures urinary symptoms. It measures the level of urinary symptoms (including incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia) reported as the total IPSS score. Each of the 7 questions has a 6-point response scale (0=none/not at all to 5=almost always) with a total score that can range from 0-35: mild (0-7), moderate (8-19), or severe (20-35). Estimates are based on adjusted (least squares) means from the general linear model: change from baseline IPSS = Treatment + Cluster + Baseline IPSS.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1575"/>
                <count group_id="O2" value="1592"/>
                <count group_id="O3" value="1582"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="0.15"/>
                    <measurement group_id="O2" value="-4.2" spread="0.15"/>
                    <measurement group_id="O3" value="-4.5" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" spread="0.15"/>
                    <measurement group_id="O2" value="-4.9" spread="0.15"/>
                    <measurement group_id="O3" value="-4.3" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="0.16"/>
                    <measurement group_id="O2" value="-5.2" spread="0.16"/>
                    <measurement group_id="O3" value="-4.0" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="0.16"/>
                    <measurement group_id="O2" value="-5.3" spread="0.16"/>
                    <measurement group_id="O3" value="-3.8" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12, 24, 36, and 48</title>
        <description>Peak maximum urinary flow (Qmax) of urinary flow using a Medtronic (formerly Dantec) Uroflow Meter (Urodyn 1000 or Duet models) with a Thompson filter was measured. Estimates are based on adjusted (least squares) means from the general linear model: Change from baseline Qmax = treatment + cluster + baseline Qmax.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Also, assessments with voided volumes &lt;125 ml were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12, 24, 36, and 48</title>
          <description>Peak maximum urinary flow (Qmax) of urinary flow using a Medtronic (formerly Dantec) Uroflow Meter (Urodyn 1000 or Duet models) with a Thompson filter was measured. Estimates are based on adjusted (least squares) means from the general linear model: Change from baseline Qmax = treatment + cluster + baseline Qmax.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Also, assessments with voided volumes &lt;125 ml were not included in the analysis.</population>
          <units>milliliters (mL)/second (sec)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1495"/>
                <count group_id="O2" value="1505"/>
                <count group_id="O3" value="1523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12, n=1477, 1482, 1510</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.12"/>
                    <measurement group_id="O2" value="1.5" spread="0.12"/>
                    <measurement group_id="O3" value="0.9" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n= 1492, 1501, 1519</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.12"/>
                    <measurement group_id="O2" value="1.9" spread="0.12"/>
                    <measurement group_id="O3" value="0.9" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36, n= 1495, 1504, 1521</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.12"/>
                    <measurement group_id="O2" value="1.9" spread="0.12"/>
                    <measurement group_id="O3" value="0.6" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48, n= 1495, 1505, 1523</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="0.13"/>
                    <measurement group_id="O2" value="2.0" spread="0.13"/>
                    <measurement group_id="O3" value="0.7" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Percent Change From Baseline in Prostate Volume at Months 12, 24, 36, and 48</title>
        <description>Prostate volume measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total prostate volume centimeters (cc). Percent change from baseline = [(post-baseline - baseline)/baseline value] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: log(post-baseline/baseline value) + treatment + cluster + log(baseline value) and are reported as percent change from baseline.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Also, prostate measurements were either not performed or missing for some participants at various timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Percent Change From Baseline in Prostate Volume at Months 12, 24, 36, and 48</title>
          <description>Prostate volume measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total prostate volume centimeters (cc). Percent change from baseline = [(post-baseline - baseline)/baseline value] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: log(post-baseline/baseline value) + treatment + cluster + log(baseline value) and are reported as percent change from baseline.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Also, prostate measurements were either not performed or missing for some participants at various timepoints.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1430"/>
                <count group_id="O2" value="1455"/>
                <count group_id="O3" value="1468"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12, n=1411, 1442, 1451</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.1" spread="0.60"/>
                    <measurement group_id="O2" value="-25.2" spread="0.59"/>
                    <measurement group_id="O3" value="-1.5" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n= 1427, 1451, 1465</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.9" spread="0.62"/>
                    <measurement group_id="O2" value="-28.0" spread="0.61"/>
                    <measurement group_id="O3" value="0.0" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36, n= 1430, 1455, 1468</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.6" spread="0.68"/>
                    <measurement group_id="O2" value="-28.8" spread="0.66"/>
                    <measurement group_id="O3" value="1.6" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48, n= 1430, 1455, 1468</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.3" spread="0.66"/>
                    <measurement group_id="O2" value="-28.0" spread="0.65"/>
                    <measurement group_id="O3" value="4.6" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12, 24, 36, and 48</title>
        <description>Prostate volume (PV) measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total PV in centimeters (cc). Results are for the transition zone measurements of the prostate in a small subset of participants. Percent change from baseline (BL) = [(post-BL - BL)/BL value] x 100. Estimates are based on the adjusted (least squares) means for the general linear model: log(post-BL/BL value) = treatment + cluster + log(BL value) and are reported as percent change from BL.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Transition zone measurements were only done on a subset of participants at sites with experience in measuring the transition zone of the prostate. Also, transition zone measurements were either not performed or missing for some participants at various timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12, 24, 36, and 48</title>
          <description>Prostate volume (PV) measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total PV in centimeters (cc). Results are for the transition zone measurements of the prostate in a small subset of participants. Percent change from baseline (BL) = [(post-BL - BL)/BL value] x 100. Estimates are based on the adjusted (least squares) means for the general linear model: log(post-BL/BL value) = treatment + cluster + log(BL value) and are reported as percent change from BL.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Transition zone measurements were only done on a subset of participants at sites with experience in measuring the transition zone of the prostate. Also, transition zone measurements were either not performed or missing for some participants at various timepoints.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
                <count group_id="O2" value="164"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12, n= 150, 159, 160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.2" spread="3.29"/>
                    <measurement group_id="O2" value="-15.6" spread="3.39"/>
                    <measurement group_id="O3" value="5.6" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n= 153, 164, 160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.4" spread="5.63"/>
                    <measurement group_id="O2" value="-22.8" spread="5.86"/>
                    <measurement group_id="O3" value="8.7" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36, n= 155, 164, 162</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.9" spread="3.97"/>
                    <measurement group_id="O2" value="-26.7" spread="3.90"/>
                    <measurement group_id="O3" value="14.7" spread="5.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48, n= 155, 164, 163</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.9" spread="4.45"/>
                    <measurement group_id="O2" value="-26.5" spread="4.21"/>
                    <measurement group_id="O3" value="18.2" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit</title>
        <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: &quot;Has the participant needed to make any unscheduled visits to his general practitioner (GP)/Urologist regarding AUR symptoms since the last study visit?&quot; If the answer to the question was “yes,” the number of visits was recorded.</description>
        <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit</title>
          <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: &quot;Has the participant needed to make any unscheduled visits to his general practitioner (GP)/Urologist regarding AUR symptoms since the last study visit?&quot; If the answer to the question was “yes,” the number of visits was recorded.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
          <units>visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1550"/>
                <count group_id="O2" value="1581"/>
                <count group_id="O3" value="1565"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3, n=1550, 1581, 1565</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, n=1479, 1517, 1514</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, n=1439, 1465, 1477</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, n=1400, 1431, 1434</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, n=1343, 1386, 1380</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, n=1318, 1350, 1328</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, n=1281, 1326, 1287</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n=1263, 1293, 1244</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27, n=1233, 1262, 1206</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30, n=1222, 1221, 1166</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33, n=1202, 1199, 1128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36, n=1187, 1174, 1095</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 39, n=1160, 1144, 1055</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42, n=1149, 1126, 1035</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 45, n=1129, 1110, 1009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48, n=1113, 1093, 990</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of &quot;Yes&quot; Responses to the Question: &quot;Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned&quot;?.</title>
        <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: &quot;Would the participant have paid a visit to his GP/Urologist regarding AUR symptoms if this study visit had not been planned?&quot;. If the answer to the question was “yes,” the number of Yes responses was recorded.</description>
        <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of &quot;Yes&quot; Responses to the Question: &quot;Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned&quot;?.</title>
          <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: &quot;Would the participant have paid a visit to his GP/Urologist regarding AUR symptoms if this study visit had not been planned?&quot;. If the answer to the question was “yes,” the number of Yes responses was recorded.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
          <units>yes responses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1550"/>
                <count group_id="O2" value="1581"/>
                <count group_id="O3" value="1564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3, n=1550, 1581, 1564</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, n=1479, 1516, 1513</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, n=1439, 1465, 1477</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, n=1400, 1431, 1434</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, n=1343, 1386, 1380</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, n=1318, 1350, 1328</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, n=1281, 1326, 1287</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n=1263, 1293, 1244</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27, n=1233, 1262, 1206</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30, n=1222, 1221, 1166</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33, n=1202, 1199, 1128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36, n=1187, 1174, 1095</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 39, n=1160, 1144, 1055</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42, n=1149, 1126, 1035</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 45, n=1129, 1110, 1009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48, n=1113, 1093, 990</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit</title>
        <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: &quot;Has the participant needed to visit his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?&quot;. If the answer to the question was “yes,” the number of visits was recorded.</description>
        <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit</title>
          <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: &quot;Has the participant needed to visit his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?&quot;. If the answer to the question was “yes,” the number of visits was recorded.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
          <units>visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1550"/>
                <count group_id="O2" value="1581"/>
                <count group_id="O3" value="1564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3, n=1550, 1581, 1564</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, n=1479, 1517, 1514</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, n=1439, 1465, 1477</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, n=1400, 1431, 1434</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, n=1343, 1386, 1380</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, n=1318, 1350, 1328</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, n=1281, 1326, 1287</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n=1263, 1293, 1244</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27, n=1233, 1262, 1206</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30, n=1222, 1221, 1165</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33, n=1202, 1199, 1128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36, n=1187, 1174, 1095</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 39, n=1160, 1144, 1055</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42, n=1149, 1126, 1035</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 45, n=1129, 1110, 1009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48, n=1113, 1093, 990</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of &quot;Yes&quot; Responses to the Question: &quot;Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?&quot;</title>
        <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: &quot;Would the participant have paid a visit to his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?&quot;. If the answer to the question was “yes,” the number of Yes responses was recorded.</description>
        <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
        <population>ITT Population. As study progressed, participants dropped out of study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of &quot;Yes&quot; Responses to the Question: &quot;Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?&quot;</title>
          <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: &quot;Would the participant have paid a visit to his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?&quot;. If the answer to the question was “yes,” the number of Yes responses was recorded.</description>
          <population>ITT Population. As study progressed, participants dropped out of study.</population>
          <units>yes responses</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1550"/>
                <count group_id="O2" value="1581"/>
                <count group_id="O3" value="1564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3, n=1550, 1581, 1564</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, n=1479, 1516, 1513</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, n=1438, 1465, 1477</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, n=1400, 1431, 1434</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, n=1343, 1386, 1380</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, n=1318, 1350, 1328</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, n=1281, 1326, 1287</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n=1263, 1293, 1244</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27, n=1233, 1262, 1206</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30, n=1222, 1221, 1166</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33, n=1202, 1199, 1128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36, n=1187, 1174, 1095</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 39, n=1160, 1144, 1055</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42, n=1149, 1126, 1034</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 45, n=1129, 1110, 1009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48, n=1113, 1093, 990</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)</title>
        <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: &quot;Has the participant had any unplanned GP/Urologist (outpatient) visits that would have taken place if a scheduled study visit had not been planned (this can include visits resulting from UTI, UI macroscopic haematuria, etc?&quot;. If the answer to the question was “yes,” the number of visits was recorded.</description>
        <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
        <population>ITT Population. As study progressed, participants dropped out of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)</title>
          <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: &quot;Has the participant had any unplanned GP/Urologist (outpatient) visits that would have taken place if a scheduled study visit had not been planned (this can include visits resulting from UTI, UI macroscopic haematuria, etc?&quot;. If the answer to the question was “yes,” the number of visits was recorded.</description>
          <population>ITT Population. As study progressed, participants dropped out of the study.</population>
          <units>visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1550"/>
                <count group_id="O2" value="1581"/>
                <count group_id="O3" value="1564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3, n=1550, 1581, 1564</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, n=1479, 1517, 1514</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, n=1439, 1465, 1477</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, n=1400, 1431, 1434</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, n=1343, 1386, 1380</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, n=1318, 1350, 1328</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, n=1281, 1326, 1287</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n=1263, 1293, 1244</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27, n=1233, 1262, 1206</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30, n=1222, 1221, 1166</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33, n=1202, 1199, 1128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36, n=1187, 1174, 1095</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 39, n=1160, 1144, 1055</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42, n=1149, 1126, 1035</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 45, n=1129, 1110, 1009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48, n=1113, 1093, 990</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Unscheduled Visits to GP/Urologist (Outpatient) Planned, Not Relating to the Study (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)</title>
        <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: &quot;Does the participant have any unscheduled GP/Urologist (outpatients) visits planned, not relating to the study (this can include visits resulting from UTI, UI, macroscopic haematuria, etc.?&quot;. If the answer to the question was “yes,” the number of visits was recorded.</description>
        <time_frame>Every 3 months from Month 3 to Month 48</time_frame>
        <population>ITT Population. As study progressed, participants dropped out the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Unscheduled Visits to GP/Urologist (Outpatient) Planned, Not Relating to the Study (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)</title>
          <description>At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: &quot;Does the participant have any unscheduled GP/Urologist (outpatients) visits planned, not relating to the study (this can include visits resulting from UTI, UI, macroscopic haematuria, etc.?&quot;. If the answer to the question was “yes,” the number of visits was recorded.</description>
          <population>ITT Population. As study progressed, participants dropped out the study.</population>
          <units>visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1550"/>
                <count group_id="O2" value="1581"/>
                <count group_id="O3" value="1564"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3, n=1550, 1581, 1564</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6, n=1479, 1516, 1514</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 9, n=1439, 1465, 1477</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, n=1400, 1431, 1434</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 15, n=1343, 1386, 1381</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18, n=1318, 1350, 1328</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 21, n=1281, 1326, 1287</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, n=1263, 1293, 1244</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 27, n=1233, 1262, 1206</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30, n=1222, 1221, 1166</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 33, n=1202, 1199, 1128</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36, n=1187, 1174, 1095</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 39, n=1160, 1144, 1055</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 42, n=1149, 1126, 1035</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 45, n=1129, 1110, 1009</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48, n=1113, 1093, 990</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in BPH Impact Index (BII) at Months 12, 24, 36, and 48</title>
        <description>The BII is a 4-item questionnaire, score range of 0 (best) to 12 (worst) for questions 1-3, and 0 (best) to 13 (worst) for question 4, that assesses the overall impact of BPH on a participant's general sense of well being and measures aspects of physical discomfort, worry, and bother, all of which can be affected by BPH and its symptoms. BII score = sum of questions 1-4. Change from baseline = Post-Baseline Value. Estimates are based on the adjusted (least squares) means from the general linear model: change from baseline BII = treatment + cluster + baseline BII.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in BPH Impact Index (BII) at Months 12, 24, 36, and 48</title>
          <description>The BII is a 4-item questionnaire, score range of 0 (best) to 12 (worst) for questions 1-3, and 0 (best) to 13 (worst) for question 4, that assesses the overall impact of BPH on a participant's general sense of well being and measures aspects of physical discomfort, worry, and bother, all of which can be affected by BPH and its symptoms. BII score = sum of questions 1-4. Change from baseline = Post-Baseline Value. Estimates are based on the adjusted (least squares) means from the general linear model: change from baseline BII = treatment + cluster + baseline BII.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1574"/>
                <count group_id="O2" value="1593"/>
                <count group_id="O3" value="1582"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.06"/>
                    <measurement group_id="O2" value="-1.5" spread="0.06"/>
                    <measurement group_id="O3" value="-1.6" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.07"/>
                    <measurement group_id="O2" value="-1.7" spread="0.07"/>
                    <measurement group_id="O3" value="-1.5" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="0.07"/>
                    <measurement group_id="O2" value="-1.8" spread="0.07"/>
                    <measurement group_id="O3" value="-1.3" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="0.07"/>
                    <measurement group_id="O2" value="-1.8" spread="0.07"/>
                    <measurement group_id="O3" value="-1.2" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change From Baseline in BPH-Related Health Status (BHS) at Months 12, 24, 36, and 48</title>
        <description>The effect of study treatment on BHS was assessed by using three self-administered questionnaires: the International Prostate Symptom Score (IPSS), the BPH Impact Index (BII), and Patient Perception of Study Medication (PPSM). The BHS score was collected on the IPPS questionnaire and ranged from 0 (best) to 6 (worst). Percent change from baseline = [(post-baseline – baseline)/baseline value] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: change from baseline BPH-related health status = treatment + cluster + baseline BPH-Related health status.</description>
        <time_frame>Baseline and Months 12, 24, 36, 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change From Baseline in BPH-Related Health Status (BHS) at Months 12, 24, 36, and 48</title>
          <description>The effect of study treatment on BHS was assessed by using three self-administered questionnaires: the International Prostate Symptom Score (IPSS), the BPH Impact Index (BII), and Patient Perception of Study Medication (PPSM). The BHS score was collected on the IPPS questionnaire and ranged from 0 (best) to 6 (worst). Percent change from baseline = [(post-baseline – baseline)/baseline value] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: change from baseline BPH-related health status = treatment + cluster + baseline BPH-Related health status.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study.</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1575"/>
                <count group_id="O2" value="1592"/>
                <count group_id="O3" value="1583"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.03"/>
                    <measurement group_id="O2" value="-1.0" spread="0.03"/>
                    <measurement group_id="O3" value="-1.0" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.03"/>
                    <measurement group_id="O2" value="-1.1" spread="0.03"/>
                    <measurement group_id="O3" value="-1.1" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.03"/>
                    <measurement group_id="O2" value="-1.2" spread="0.03"/>
                    <measurement group_id="O3" value="-1.1" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="0.03"/>
                    <measurement group_id="O2" value="-1.3" spread="0.03"/>
                    <measurement group_id="O3" value="-1.1" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 1 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has control of your urinary problems changed?&quot;.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 1 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has control of your urinary problems changed?&quot;.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1685"/>
                <count group_id="O2" value="1600"/>
                <count group_id="O3" value="1586"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL), Any Improvement, n=1585, 1600, 1586</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="696"/>
                    <measurement group_id="O2" value="656"/>
                    <measurement group_id="O3" value="706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, No Change/Any Worsening, n=1585, 1600, 1586</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="889"/>
                    <measurement group_id="O2" value="944"/>
                    <measurement group_id="O3" value="880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month (M) 12, Any Improvement, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1281"/>
                    <measurement group_id="O2" value="1171"/>
                    <measurement group_id="O3" value="1218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12, No Change/Any Worsening, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                    <measurement group_id="O2" value="422"/>
                    <measurement group_id="O3" value="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Any Improvement, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1273"/>
                    <measurement group_id="O2" value="1200"/>
                    <measurement group_id="O3" value="1195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, No Change/Any Worsening, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="393"/>
                    <measurement group_id="O3" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Any Improvement, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1268"/>
                    <measurement group_id="O2" value="1203"/>
                    <measurement group_id="O3" value="1152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, No Change/Any Worsening, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308"/>
                    <measurement group_id="O2" value="390"/>
                    <measurement group_id="O3" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Any Improvement, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1278"/>
                    <measurement group_id="O2" value="1212"/>
                    <measurement group_id="O3" value="1138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, No Change/Any Worsening, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298"/>
                    <measurement group_id="O2" value="381"/>
                    <measurement group_id="O3" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 2 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect of the study medication on control of your urinary problems?&quot; Satisfact., satisfaction.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 2 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect of the study medication on control of your urinary problems?&quot; Satisfact., satisfaction.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1587"/>
                <count group_id="O2" value="1600"/>
                <count group_id="O3" value="1583"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL), Any Satisfact., n=1587, 1600, 1583</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="707"/>
                    <measurement group_id="O2" value="652"/>
                    <measurement group_id="O3" value="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, Neutral/Any Dissatisfact., n=1587, 1600, 1583</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="880"/>
                    <measurement group_id="O2" value="948"/>
                    <measurement group_id="O3" value="897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month (M) 12, Any Satisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1224"/>
                    <measurement group_id="O2" value="1127"/>
                    <measurement group_id="O3" value="1178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12, Neutral/Any Dissatisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352"/>
                    <measurement group_id="O2" value="466"/>
                    <measurement group_id="O3" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Any Satisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1261"/>
                    <measurement group_id="O2" value="1166"/>
                    <measurement group_id="O3" value="1150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Neutral/Any Dissatisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315"/>
                    <measurement group_id="O2" value="427"/>
                    <measurement group_id="O3" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Any Satisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1260"/>
                    <measurement group_id="O2" value="1167"/>
                    <measurement group_id="O3" value="1120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Neutral/Any Dissatisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316"/>
                    <measurement group_id="O2" value="426"/>
                    <measurement group_id="O3" value="461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Any Satisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1267"/>
                    <measurement group_id="O2" value="1172"/>
                    <measurement group_id="O3" value="1088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Neutral/Any Dissatisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="309"/>
                    <measurement group_id="O2" value="421"/>
                    <measurement group_id="O3" value="493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 3 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has the strength of your urinary stream changed?&quot;.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 3 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has the strength of your urinary stream changed?&quot;.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1585"/>
                <count group_id="O2" value="1601"/>
                <count group_id="O3" value="1585"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL), Any Improvement, n=1585, 1601, 1585</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="629"/>
                    <measurement group_id="O2" value="602"/>
                    <measurement group_id="O3" value="615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, No Change/Any Worsening, n=1585, 1601, 1585</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="956"/>
                    <measurement group_id="O2" value="999"/>
                    <measurement group_id="O3" value="970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month (M) 12, Any Improvement, n=1576, 1593, 158</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1181"/>
                    <measurement group_id="O2" value="1044"/>
                    <measurement group_id="O3" value="1105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12, No Change/Any Worsening, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="549"/>
                    <measurement group_id="O3" value="476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Any Improvement, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1215"/>
                    <measurement group_id="O2" value="1070"/>
                    <measurement group_id="O3" value="1057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, No Change/Any Worsening, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                    <measurement group_id="O2" value="523"/>
                    <measurement group_id="O3" value="524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Any Improvement, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1206"/>
                    <measurement group_id="O2" value="1071"/>
                    <measurement group_id="O3" value="1023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, No Change/Any Worsening, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370"/>
                    <measurement group_id="O2" value="522"/>
                    <measurement group_id="O3" value="558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Any Improvement, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1202"/>
                    <measurement group_id="O2" value="1086"/>
                    <measurement group_id="O3" value="1008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, No Change/Any Worsening, n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374"/>
                    <measurement group_id="O2" value="507"/>
                    <measurement group_id="O3" value="573"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 4 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect of the study medication on the strength of your urinary stream?&quot;. Satisfact., satisfaction.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 4 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect of the study medication on the strength of your urinary stream?&quot;. Satisfact., satisfaction.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1583"/>
                <count group_id="O2" value="1601"/>
                <count group_id="O3" value="1582"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL), Any Satisfact., n=1583,1601,1582</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="632"/>
                    <measurement group_id="O2" value="586"/>
                    <measurement group_id="O3" value="613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, Neutral/Any Dissatisfact., n=1583,1601,1582</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="951"/>
                    <measurement group_id="O2" value="1015"/>
                    <measurement group_id="O3" value="969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month (M) 12, Any Satisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1154"/>
                    <measurement group_id="O2" value="1037"/>
                    <measurement group_id="O3" value="1097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12, Neutral/Any Dissatisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422"/>
                    <measurement group_id="O2" value="556"/>
                    <measurement group_id="O3" value="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Any Satisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1203"/>
                    <measurement group_id="O2" value="1072"/>
                    <measurement group_id="O3" value="1051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Neutral/Any Dissatisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="373"/>
                    <measurement group_id="O2" value="521"/>
                    <measurement group_id="O3" value="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Any Satisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1201"/>
                    <measurement group_id="O2" value="1075"/>
                    <measurement group_id="O3" value="1039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Neutral/Any Dissatisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375"/>
                    <measurement group_id="O2" value="518"/>
                    <measurement group_id="O3" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Any Satisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1208"/>
                    <measurement group_id="O2" value="1089"/>
                    <measurement group_id="O3" value="1022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Neutral/Any Dissatisfact., n=1576, 1593, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368"/>
                    <measurement group_id="O2" value="504"/>
                    <measurement group_id="O3" value="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 5 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has your pain prior to urinating changed?&quot;.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 5 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has your pain prior to urinating changed?&quot;.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="869"/>
                <count group_id="O2" value="901"/>
                <count group_id="O3" value="849"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL), Any Improvement, n=869, 901, 849</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="337"/>
                    <measurement group_id="O2" value="331"/>
                    <measurement group_id="O3" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, No Change/Any Worsening, n=869, 901, 849</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="532"/>
                    <measurement group_id="O2" value="570"/>
                    <measurement group_id="O3" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month (M) 12, Any Improvement, n=769, 817, 771</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556"/>
                    <measurement group_id="O2" value="526"/>
                    <measurement group_id="O3" value="527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12, No Change/Any Worsening, n=769, 817, 771</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213"/>
                    <measurement group_id="O2" value="291"/>
                    <measurement group_id="O3" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Any Improvement, n=720, 780, 771</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="537"/>
                    <measurement group_id="O2" value="526"/>
                    <measurement group_id="O3" value="535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, No Change/Any Worsening, n=720, 780, 771</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                    <measurement group_id="O2" value="254"/>
                    <measurement group_id="O3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Any Improvement, n=714, 753, 748</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="540"/>
                    <measurement group_id="O2" value="514"/>
                    <measurement group_id="O3" value="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, No Change/Any Worsening, n=714, 753, 748</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="239"/>
                    <measurement group_id="O3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Any Improvement, n=709, 756, 751</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="531"/>
                    <measurement group_id="O2" value="510"/>
                    <measurement group_id="O3" value="489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, No Change/Any Worsening, n=709, 756, 751</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="246"/>
                    <measurement group_id="O3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 6 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect the study medication has on your pain prior to urinating?&quot;. Satisfact., satisfaction.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 6 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect the study medication has on your pain prior to urinating?&quot;. Satisfact., satisfaction.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1135"/>
                <count group_id="O2" value="1223"/>
                <count group_id="O3" value="1161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL), Any Satisfact., n=908, 932, 889</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375"/>
                    <measurement group_id="O2" value="351"/>
                    <measurement group_id="O3" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, Neutral/Any Dissatisfact., n=908, 932, 889</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="533"/>
                    <measurement group_id="O2" value="581"/>
                    <measurement group_id="O3" value="538"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month (M) 12, Any Satisfact., n=1022, 1088, 1019</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="712"/>
                    <measurement group_id="O2" value="672"/>
                    <measurement group_id="O3" value="681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12, Neutral/Any Dissatisfact., n=1022, 1088, 1019</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="416"/>
                    <measurement group_id="O3" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Any Satisfact., n=1077, 1151, 1085</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="764"/>
                    <measurement group_id="O2" value="740"/>
                    <measurement group_id="O3" value="708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Neutral/Any Dissatisfact., n=1077, 1151, 1085</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313"/>
                    <measurement group_id="O2" value="411"/>
                    <measurement group_id="O3" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Any Satisfact., n=1115, 1200, 1135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="799"/>
                    <measurement group_id="O2" value="785"/>
                    <measurement group_id="O3" value="736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Neutral/Any Dissatisfact., n=1115, 1200, 1135</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="316"/>
                    <measurement group_id="O2" value="415"/>
                    <measurement group_id="O3" value="399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Any Satisfact., n=1135, 1223, 1161</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="810"/>
                    <measurement group_id="O2" value="792"/>
                    <measurement group_id="O3" value="739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Neutral/Any Dissatisfact., n=1135, 1223, 1161</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="325"/>
                    <measurement group_id="O2" value="431"/>
                    <measurement group_id="O3" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 7 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has your pain during urination changed?&quot;.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 7 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has your pain during urination changed?&quot;.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="852"/>
                <count group_id="O2" value="889"/>
                <count group_id="O3" value="822"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL), Any Improvement, n=852, 889, 822</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321"/>
                    <measurement group_id="O2" value="314"/>
                    <measurement group_id="O3" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, No Change/Any Worsening, n=852, 889, 822</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="531"/>
                    <measurement group_id="O2" value="575"/>
                    <measurement group_id="O3" value="503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month (M) 12, Any Improvement, n=760, 781, 755</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550"/>
                    <measurement group_id="O2" value="500"/>
                    <measurement group_id="O3" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12, No Change/Any Worsening, n=760, 781, 755</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="281"/>
                    <measurement group_id="O3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Any Improvement, n=706, 760, 747</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="532"/>
                    <measurement group_id="O2" value="508"/>
                    <measurement group_id="O3" value="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, No Change/Any Worsening, n=706, 760, 747</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="252"/>
                    <measurement group_id="O3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Any Improvement, n=704, 741, 733</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="529"/>
                    <measurement group_id="O2" value="504"/>
                    <measurement group_id="O3" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, No Change/Any Worsening, n=704, 741, 733</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="237"/>
                    <measurement group_id="O3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, No Change/Any Worsening, n=702, 739, 740</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="252"/>
                    <measurement group_id="O3" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Any Improvement, n=702, 739, 740</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="527"/>
                    <measurement group_id="O2" value="487"/>
                    <measurement group_id="O3" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 8 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect the study medication has on your pain during urination?&quot;. Satisfact., satisfaction.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 8 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect the study medication has on your pain during urination?&quot;. Satisfact., satisfaction.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1146"/>
                <count group_id="O2" value="1224"/>
                <count group_id="O3" value="1160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL), Any Satisfact., n=890, 925, 851</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354"/>
                    <measurement group_id="O2" value="348"/>
                    <measurement group_id="O3" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, Neutral/Any Dissatisfact., n=890, 925, 851</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="536"/>
                    <measurement group_id="O2" value="577"/>
                    <measurement group_id="O3" value="518"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month (M) 12, Any Satisfact., n=1022, 1088, 1011</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="712"/>
                    <measurement group_id="O2" value="655"/>
                    <measurement group_id="O3" value="678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12, Neutral/Any Dissatisfact., n=1022, 1088, 1011</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="433"/>
                    <measurement group_id="O3" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Any Satisfact., n=1077, 1155, 1079</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="763"/>
                    <measurement group_id="O2" value="730"/>
                    <measurement group_id="O3" value="708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Neutral/Any Dissatisfact., n=1077, 1155, 1079</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314"/>
                    <measurement group_id="O2" value="425"/>
                    <measurement group_id="O3" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Any Satisfact., n=1121, 1206, 1131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="807"/>
                    <measurement group_id="O2" value="784"/>
                    <measurement group_id="O3" value="724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Neutral/Any Dissatisfact., n=1121, 1206, 1131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314"/>
                    <measurement group_id="O2" value="422"/>
                    <measurement group_id="O3" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Any Satsifact., n=1146,1224,1160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="827"/>
                    <measurement group_id="O2" value="785"/>
                    <measurement group_id="O3" value="729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Neutral/Any Dissatisfact., n=1146, 1224, 1160</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                    <measurement group_id="O2" value="439"/>
                    <measurement group_id="O3" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 9 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has the way your urinary problems interfere with your ability to go about your usual activities changed?&quot;.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 9 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Since you began taking the study medication, how has the way your urinary problems interfere with your ability to go about your usual activities changed?&quot;.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1575"/>
                <count group_id="O2" value="1593"/>
                <count group_id="O3" value="1580"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL), Any Improvement, n=1574, 1599, 1575</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509"/>
                    <measurement group_id="O2" value="481"/>
                    <measurement group_id="O3" value="494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, No Change/Any Worsening, n=1574, 1599, 1575</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1065"/>
                    <measurement group_id="O2" value="1118"/>
                    <measurement group_id="O3" value="1081"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month (M) 12, Any Improvement, n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1124"/>
                    <measurement group_id="O2" value="1027"/>
                    <measurement group_id="O3" value="1084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12, No Change/Any Worsening, n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451"/>
                    <measurement group_id="O2" value="566"/>
                    <measurement group_id="O3" value="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Any Improvement, n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1146"/>
                    <measurement group_id="O2" value="1053"/>
                    <measurement group_id="O3" value="1049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, No Change/Any Worsening, n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429"/>
                    <measurement group_id="O2" value="540"/>
                    <measurement group_id="O3" value="531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Any Improvement, n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1575"/>
                    <measurement group_id="O2" value="1593"/>
                    <measurement group_id="O3" value="1580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, No Change/Any Worsening, n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412"/>
                    <measurement group_id="O2" value="529"/>
                    <measurement group_id="O3" value="553"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Any Improvement, n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1148"/>
                    <measurement group_id="O2" value="1063"/>
                    <measurement group_id="O3" value="1008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, No Change/Any Worsening, n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="427"/>
                    <measurement group_id="O2" value="530"/>
                    <measurement group_id="O3" value="572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 10 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect the study medication has on your ability to go about your usual activities without interference from your urinary problems?&quot;. Satisfact., satisfaction.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 10 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;How satisfied are you with the effect the study medication has on your ability to go about your usual activities without interference from your urinary problems?&quot;. Satisfact., satisfaction.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1575"/>
                <count group_id="O2" value="1593"/>
                <count group_id="O3" value="1580"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL), Any Satisfact., n=1574, 1600, 1576</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="611"/>
                    <measurement group_id="O2" value="565"/>
                    <measurement group_id="O3" value="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, Neutral /Any Dissatisfact., n=1574, 1600, 1576</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="963"/>
                    <measurement group_id="O2" value="1035"/>
                    <measurement group_id="O3" value="992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month (M) 12, Any Satisfact., n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1176"/>
                    <measurement group_id="O2" value="1073"/>
                    <measurement group_id="O3" value="1114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12, Neutral/Any Dissatisfact., n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399"/>
                    <measurement group_id="O2" value="520"/>
                    <measurement group_id="O3" value="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Any Satisfact., n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1205"/>
                    <measurement group_id="O2" value="1116"/>
                    <measurement group_id="O3" value="1088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Neutral/Any Dissatisfact., n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370"/>
                    <measurement group_id="O2" value="477"/>
                    <measurement group_id="O3" value="492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Any Satisfact., n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1210"/>
                    <measurement group_id="O2" value="1098"/>
                    <measurement group_id="O3" value="1074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Neutral/Any Dissatisfact., n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365"/>
                    <measurement group_id="O2" value="495"/>
                    <measurement group_id="O3" value="506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Any Satisfact., n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1213"/>
                    <measurement group_id="O2" value="1123"/>
                    <measurement group_id="O3" value="1043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Neutral/Any Dissatisfact., n=1575, 1593, 1580</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="362"/>
                    <measurement group_id="O2" value="470"/>
                    <measurement group_id="O3" value="537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 11 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Overall, how satisfied are you with the study medication and it's effect on your urinary problems?&quot;. Satisfact., satisfaction.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 11 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Overall, how satisfied are you with the study medication and it's effect on your urinary problems?&quot;. Satisfact., satisfaction.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1574"/>
                <count group_id="O2" value="1592"/>
                <count group_id="O3" value="1581"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL), Any Satisfact., n=1573, 1598, 1574</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="717"/>
                    <measurement group_id="O2" value="683"/>
                    <measurement group_id="O3" value="699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, Neutral/Any Dissatisfact., n=1573, 1598, 1574</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="856"/>
                    <measurement group_id="O2" value="915"/>
                    <measurement group_id="O3" value="875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month (M) 12, Any Satisfact., n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="1159"/>
                    <measurement group_id="O3" value="1202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M12, Neutral/Any Dissatisfact., n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324"/>
                    <measurement group_id="O2" value="433"/>
                    <measurement group_id="O3" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Any Satisfact., n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1279"/>
                    <measurement group_id="O2" value="1188"/>
                    <measurement group_id="O3" value="1163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M24, Neutral/Any Dissatisfact., n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                    <measurement group_id="O2" value="404"/>
                    <measurement group_id="O3" value="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Any Satisfact., n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1270"/>
                    <measurement group_id="O2" value="1188"/>
                    <measurement group_id="O3" value="1119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M36, Neutral/Any Dissatisfact., n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304"/>
                    <measurement group_id="O2" value="404"/>
                    <measurement group_id="O3" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Any Satifact., n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1262"/>
                    <measurement group_id="O2" value="1182"/>
                    <measurement group_id="O3" value="1097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M48, Neutral/Any Dissatisfact., n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="312"/>
                    <measurement group_id="O2" value="410"/>
                    <measurement group_id="O3" value="484"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 12 (LOCF)</title>
        <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Would you ask your doctor for the medication you received in this study?&quot;.</description>
        <time_frame>Baseline and Months 12, 24, 36, and 48</time_frame>
        <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg</title>
            <description>Dutasteride 0.5 milligrams (mg) plus tamsulosin 0.4 mg once daily for 208 weeks</description>
          </group>
          <group group_id="O2">
            <title>Dutasteride 0.5 mg</title>
            <description>Dutasteride 0.5 mg plus tamsulosin placebo once daily for 208 weeks</description>
          </group>
          <group group_id="O3">
            <title>Tamsulosin 0.4 mg</title>
            <description>Tamsulosin 0.4 mg plus dutasteride placebo once daily for 208 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 12 (LOCF)</title>
          <description>This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of &quot;Would you ask your doctor for the medication you received in this study?&quot;.</description>
          <population>ITT Population. As the study progressed, participants dropped out of the study. Only participants responding to the question were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1574"/>
                <count group_id="O2" value="1592"/>
                <count group_id="O3" value="1581"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline, Yes, n=1560, 1579, 1562</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="587"/>
                    <measurement group_id="O2" value="557"/>
                    <measurement group_id="O3" value="582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline, No/Not Sure, n=1560, 1579, 1562</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="973"/>
                    <measurement group_id="O2" value="1022"/>
                    <measurement group_id="O3" value="980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Yes, n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="972"/>
                    <measurement group_id="O2" value="920"/>
                    <measurement group_id="O3" value="970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, No/Not Sure, n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="602"/>
                    <measurement group_id="O2" value="671"/>
                    <measurement group_id="O3" value="611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, Yes, n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1027"/>
                    <measurement group_id="O2" value="955"/>
                    <measurement group_id="O3" value="952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24, No/Not Sure, n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547"/>
                    <measurement group_id="O2" value="636"/>
                    <measurement group_id="O3" value="629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36, Yes, n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1031"/>
                    <measurement group_id="O2" value="956"/>
                    <measurement group_id="O3" value="915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36, No/Not Sure, n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="543"/>
                    <measurement group_id="O2" value="636"/>
                    <measurement group_id="O3" value="666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48, Yes, n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1003"/>
                    <measurement group_id="O2" value="918"/>
                    <measurement group_id="O3" value="874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48, No/Not Sure, n=1574, 1592, 1581</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="571"/>
                    <measurement group_id="O2" value="674"/>
                    <measurement group_id="O3" value="707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Combination</title>
        </group>
        <group group_id="E2">
          <title>Dutasteride 0.5 mg</title>
        </group>
        <group group_id="E3">
          <title>Tamsulosin 0.4 mg</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="303" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="339" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="348" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>AV dissociation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cardiac asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Coronary artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cardiovascular deconditioning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hypertensive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Chronic left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hereditary sideroblastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Inguinal hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Abdominal rigidity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pharyngoesophageal diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Appendix disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Anal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Implant site erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Urniary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Urosepis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Abcess intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Epiglottitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Escherichia coli</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Infective myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Prostatic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Central line infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Epidemic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Epicodylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Medical device complicaiton</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lung injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Post procedural constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Chest x-ray abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Coagulation factor decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Nose deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pancreatic neolasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Benign colonic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Brain neoplasm benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Central nervous system lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of Vater</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Malignant palate neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Metastatic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Multiple myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Retinal melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Tracheal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Urinary bladder adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastrointestinal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Retroperitoneal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Urinary tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Brain stem ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Grand mal convulsions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Intracranial hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Radicular pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cerebral cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Nephrotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Urinary bladder haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Ureteral polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Renal artery arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Epididymal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Prostatic intraepithelial neoplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Idioipathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Allergic granulomatous angiitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Purpura senile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Malignant hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Venous stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Arterial stenosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Aortic dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Aortic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Arterial disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="618" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="586" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="590" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="149" subjects_at_risk="1611"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="83" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="113" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="167" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="1610"/>
                <counts group_id="E2" subjects_affected="147" subjects_at_risk="1623"/>
                <counts group_id="E3" subjects_affected="136" subjects_at_risk="1611"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

